Breakthrough in Immunology: Development of CNS-Tau-Specific Antibodies

Strategic Insights -

Researchers at Brigham and Women's Hospital have made a significant discovery in the field of immunology, developing two CNS-tau-specific monoclonal antibodies that can be used to diagnose and understand the progression of tau-related neurodegenerative diseases such as Alzheimer's disease. The antibodies, LL-T-1-1 and LL-T-1-5, were created to target a specific sequence of the tau protein encoded by exons 4 and 5. Studies have shown that these antibodies are highly specific and can distinguish between different types of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and corticobasal degeneration.

Key Takeaways:

  • The research aimed to develop CNS-tau-specific monoclonal antibodies to assess their utility in neuropathology and fluid-based biomarker assays across AD and primary tauopathies.
  • Six recombinant rabbit monoclonal antibodies were generated targeting a CNS-tau-specific sequence encoded by exons 4 and 5, with specificity and affinity evaluated via biolayer interferometry, immunoblotting, and tau-expressing HEK293 models.
  • The lead clone, LL-T-1-1, showed specificity for CNS-tau in postmortem brain sections from 23 patients with Alzheimer's disease, 3 patients with progressive supranuclear palsy, and 3 patients with corticobasal degeneration.
  • A second clone, LL-T-1-5, was optimized for use in plasma assays via an ultrasensitive nanoneedle platform, with a limit of detection (LoD) of 0.5 pg/mL.
  • The CNS-tau-specific antibodies LL-T-1-1 and LL-T-1-5 provide new tools for neuropathology and fluid biomarker development across tauopathies.

Statistics:

  • 23 postmortem brain sections from patients with Alzheimer's disease
  • 3 postmortem brain sections from patients with progressive supranuclear palsy
  • 3 postmortem brain sections from patients with corticobasal degeneration
  • 0.5 pg/mL limit of detection (LoD) for LL-T-1-5
  • 6 recombinant rabbit monoclonal antibodies generated
  • 2 CNS-tau-specific antibodies developed (LL-T-1-1 and LL-T-1-5)

Sources:

  • bioRxiv, 2025
  • NewsRx. Study Results from Brigham and Women's Hospital Broaden Understanding of Immunoglobulins (CNS-Tau Specific Antibodies Illuminate Disease Signatures Across Tauopathies). Life Science Weekly. October 21, 2025; p 7898.